Keros Therapeutics Q3 EPS $(1.33) Beats $(1.35) Estimate; Cash And Cash Equivalents Of $287.9M Is Expected To Fund Its Operating Expenses And Capital Expenditure Requirements Into Q4 Of 2025
Portfolio Pulse from Benzinga Newsdesk
Keros Therapeutics reported Q3 losses of $(1.33) per share, beating the analyst consensus estimate of $(1.35) by 1.48 percent. This is a 44.57 percent increase in losses from the same period last year. The company's cash and cash equivalents of $287.9M are expected to fund its operating expenses and capital expenditure requirements into Q4 of 2025.
November 06, 2023 | 1:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Keros Therapeutics reported better than expected Q3 losses and has sufficient cash to fund operations until Q4 2025.
Keros Therapeutics reported a smaller than expected loss for Q3, which is generally seen as positive by investors. Additionally, the company's significant cash reserves, which are expected to fund operations until Q4 2025, provide a level of financial stability that may also be viewed favorably by the market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100